Business Context and Reporting Period
This Form 6-K filing by Alpha Tau Medical Ltd. covers the month of June 2026, specifically dated June 11, 2026. The report serves to disseminate a press release regarding significant clinical trial progress for the Company's REGAIN Recurrent Glioblastoma trial.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical developments rather than financial performance.
Material Changes
The primary material change reported is the receipt of FDA clearance to complete enrollment in the REGAIN Recurrent Glioblastoma trial. Additionally, the Company announced the addition of two new U.S. clinical sites. Early interim results from the trial demonstrated 100% local disease control.
Guidance, Outlook, and Risks
Management commentary is limited to the press release details regarding the trial's advancement. The filing does not contain specific financial guidance, updated outlooks, or a discussion of risks and contingencies beyond the standard legal disclaimers regarding the non-filing status of the exhibit.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed trial methodology.
- Confirm the specific locations of the two new U.S. clinical sites.
- Review the definition and statistical significance of the "100% local disease control" metric in the interim results.
- Monitor subsequent filings for enrollment completion dates and final trial outcomes.